The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia.
Twenty-five women with preeclampsia who were scheduled to undergo cesarean section under general anesthesia were randomly assigned to either a labetalol pretreatment group (n = 15) or a control group (n = 10) who did not receive any antihypertensive therapy before the induction of anesthesia. Patients in the labetalol group received 20 mg of labetalol intravenously followed by 10 mg increments up to a total dose of 1 mg/kg, which resulted in moderate reductions in the maternal mean arterial pressure and heart rate with attenuation of the hypertensive and tachycardiac responses to laryngoscopy and endotracheal intubation. In the labetalol group there was no excessive reduction in the mean arterial pressure with the use of isoflurane and the usual amount of blood loss that occurred during cesarean section. The neonatal Apgar scores and umbilical arterial and venous pH and blood gas values were similar in the two groups. Side effects such as hypotension, bradycardia, and hypoglycemia were not seen in the neonates in the labetalol treatment group.
Ramanathan
J
J
Department of Anesthesiology, University of Tennessee, Memphis.
Sibai
B M
BM
Mabie
W C
WC
Chauhan
D
D
Ruiz
A G
AG
D000293:Adolescent; D000328:Adult; D000773:Anesthesia, Obstetrical / Q000009:adverse effects; D001794:Blood Pressure / Q000187:drug effects; D002585:Cesarean Section; D005260:Female; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control*; D007231:Infant, Newborn; D007442:Intubation, Intratracheal / Q000009:adverse effects*; D007741:Labetalol / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000503:physiopathology*; D011247:Pregnancy; D012018:Reflex / Q000187:drug effects; D013610:Tachycardia / Q000209:etiology / Q000517:prevention & control
D007741:Labetalol